相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
Tomohiro Aoki et al.
CANCER DISCOVERY (2020)
High-dimensional immune-profiling in cancer: implications for immunotherapy
Samuel Chuah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
Yosuke Togashi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Daisuke Ennishi et al.
CANCER DISCOVERY (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
Tyler R. McCaw et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Margaret L. Axelrod et al.
CLINICAL CANCER RESEARCH (2019)
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion
Kirsty Wienand et al.
BLOOD ADVANCES (2019)
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment
Fathima Zumla Cader et al.
BLOOD (2018)
Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells
Marc A. Weniger et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
Yasuko Tada et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B. Johnson et al.
JCI INSIGHT (2018)
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
Mika Shapiro et al.
HAEMATOLOGICA (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma
Zhi-Zhang Yang et al.
ONCOTARGET (2017)
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
Mika Shapiro et al.
HAEMATOLOGICA (2017)
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
Marcel Nijland et al.
ONCOIMMUNOLOGY (2017)
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
W. Robert Liu et al.
BLOOD (2017)
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Christopher D. Carey et al.
BLOOD (2017)
Check point inhibitors as therapies for infectious diseases
Maureen A. Cox et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy
Amy S. Duffield et al.
BLOOD ADVANCES (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
CRT AM determines the CD4+ cytotoxic T lymphocyte lineage
Arata Takeuchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Hodgkin lymphoma: Pathology and biology
Stephan Mathas et al.
SEMINARS IN HEMATOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Margaretha G. M. Roemer et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
Jonathan Reichel et al.
BLOOD (2015)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Antje Sucker et al.
CLINICAL CANCER RESEARCH (2014)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
The MHC I loading complex: a multitasking machinery in adaptive immunity
Sabine Hulpke et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Ying Xie et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients
Maher K. Gandhi et al.
BLOOD (2006)
Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells
R Meazza et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
分享论文
